Cargando…

Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals

A series of antisense oligonucleotides (ASOs) containing either 2′-O-methoxyethylribose (MOE) or locked nucleic acid (LNA) modifications were designed to investigate whether LNA antisense oligonucleotides (ASOs) have the potential to improve upon MOE based ASO therapeutics. Some, but not all, LNA co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Swayze, Eric E., Siwkowski, Andrew M., Wancewicz, Edward V., Migawa, Michael T., Wyrzykiewicz, Tadeusz K., Hung, Gene, Monia, Brett P., Bennett, and C. Frank
Formato:	Texto
Lenguaje:	English
Publicado:	Oxford University Press 2007
Materias:	Chemistry
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1802611/ https://www.ncbi.nlm.nih.gov/pubmed/17182632 http://dx.doi.org/10.1093/nar/gkl1071

Ejemplares similares

Sequence motifs associated with hepatotoxicity of locked nucleic acid—modified antisense oligonucleotides
por: Burdick, Andrew D., et al.
Publicado: (2014)

Ribonuclease H1-dependent hepatotoxicity caused by locked nucleic acid-modified gapmer antisense oligonucleotides
por: Kasuya, Takeshi, et al.
Publicado: (2016)

Understanding the effect of controlling phosphorothioate chirality in the DNA gap on the potency and safety of gapmer antisense oligonucleotides
por: Østergaard, Michael E, et al.
Publicado: (2020)

Targeting murine alveolar macrophages by the intratracheal administration of locked nucleic acid containing antisense oligonucleotides
por: Uemura, Yasunori, et al.
Publicado: (2019)

Fatty acid conjugation enhances potency of antisense oligonucleotides in muscle
por: Prakash, Thazha P, et al.
Publicado: (2019)

Synthesis, biophysical properties and biological activity of second generation antisense oligonucleotides containing chiral phosphorothioate linkages
por: Wan, W. Brad, et al.
Publicado: (2014)

Intracerebral Infusion of Antisense Oligonucleotides Into Prion-infected Mice
por: Nazor Friberg, Karah, et al.
Publicado: (2012)

The intratracheal administration of locked nucleic acid containing antisense oligonucleotides induced gene silencing and an immune-stimulatory effect in the murine lung
por: Uemura, Yasunori, et al.
Publicado: (2017)

Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents
por: Stein, C. A., et al.
Publicado: (2010)

Synthesis and biophysical properties of carbamate-locked nucleic acid (LNA) oligonucleotides with potential antisense applications
por: Thorpe, Cameron, et al.
Publicado: (2019)

Chemical Diversity of Locked Nucleic Acid-Modified Antisense Oligonucleotides Allows Optimization of Pharmaceutical Properties
por: Papargyri, Natalia, et al.
Publicado: (2019)

Identification and characterization of a MAPT-targeting locked nucleic acid antisense oligonucleotide therapeutic for tauopathies
por: Easton, Amy, et al.
Publicado: (2022)

Towards next generation antisense oligonucleotides: mesylphosphoramidate modification improves therapeutic index and duration of effect of gapmer antisense oligonucleotides
por: Anderson, Brooke A, et al.
Publicado: (2021)

Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice
por: Prakash, Thazha P., et al.
Publicado: (2014)

Alpha-l-Locked Nucleic Acid-Modified Antisense Oligonucleotides Induce Efficient Splice Modulation In Vitro
por: Raguraman, Prithi, et al.
Publicado: (2020)

Conjugation of hydrophobic moieties enhances potency of antisense oligonucleotides in the muscle of rodents and non-human primates
por: Østergaard, Michael E, et al.
Publicado: (2019)

Down-modulation of cancer targets using locked nucleic acid (LNA)-based antisense oligonucleotides without transfection
por: Zhang, Y, et al.
Publicado: (2011)

Elucidation of the Biotransformation Pathways of a Galnac(3)-conjugated Antisense Oligonucleotide in Rats and Monkeys
por: Shemesh, Colby S, et al.
Publicado: (2016)

Identification of nucleobase chemical modifications that reduce the hepatotoxicity of gapmer antisense oligonucleotides
por: Yoshida, Tokuyuki, et al.
Publicado: (2022)

A Locked Nucleic Acid Antisense Oligonucleotide (LNA) Silences PCSK9 and Enhances LDLR Expression In Vitro and In Vivo
por: Gupta, Nidhi, et al.
Publicado: (2010)

In vitro inhibition of porcine reproductive and respiratory syndrome virus replication by short antisense oligonucleotides with locked nucleic acid modification
por: Zhu, Lingyun, et al.
Publicado: (2018)

Likelihood of Nonspecific Activity of Gapmer Antisense Oligonucleotides Is Associated with Relative Hybridization Free Energy
por: Watt, Andrew T., et al.
Publicado: (2020)

Hepatotoxicity of high affinity gapmer antisense oligonucleotides is mediated by RNase H1 dependent promiscuous reduction of very long pre-mRNA transcripts
por: Burel, Sebastien A., et al.
Publicado: (2016)

RNA Interference-Guided Targeting of Hepatitis C Virus Replication with Antisense Locked Nucleic Acid-Based Oligonucleotides Containing 8-oxo-dG Modifications
por: Mutso, Margit, et al.
Publicado: (2015)

Rational Design of Short Locked Nucleic Acid-Modified 2′-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro
por: Le, Bao T., et al.
Publicado: (2017)

Targeting of Repeated Sequences Unique to a Gene Results in Significant Increases in Antisense Oligonucleotide Potency
por: Vickers, Timothy A., et al.
Publicado: (2014)

Enhanced Potency of GalNAc-Conjugated Antisense Oligonucleotides in Hepatocellular Cancer Models
por: Kim, Youngsoo, et al.
Publicado: (2019)

Intramuscular Evaluation of Chimeric Locked Nucleic Acid/2′OMethyl-Modified Antisense Oligonucleotides for Targeted Exon 23 Skipping in Mdx Mice
por: Georgiadou, Michaella, et al.
Publicado: (2021)

Treatment of transthyretin (TTR) amyloid cardiomyopathy with an antisense oligonucleotide inhibitor of TTR synthesis
por: Benson, Merrill D, et al.
Publicado: (2015)

Short locked nucleic acid antisense oligonucleotides potently reduce apolipoprotein B mRNA and serum cholesterol in mice and non-human primates
por: Straarup, Ellen Marie, et al.
Publicado: (2010)

Application of Locked Nucleic Acid Oligonucleotides for siRNA Preclinical Bioanalytics
por: Thayer, Mai B., et al.
Publicado: (2019)

Mechanisms of palmitic acid-conjugated antisense oligonucleotide distribution in mice
por: Chappell, Alfred E, et al.
Publicado: (2020)

Nucleic acid binding proteins affect the subcellular distribution of phosphorothioate antisense oligonucleotides
por: Bailey, Jeffrey K., et al.
Publicado: (2017)

Antisense oligonucleotide therapy for spinocerebellar ataxia type 2
por: Scoles, Daniel R., et al.
Publicado: (2017)

Targeting Translation Termination Machinery with Antisense Oligonucleotides for Diseases Caused by Nonsense Mutations
por: Huang, Lulu, et al.
Publicado: (2019)

Fluorinated Nucleotide Modifications Modulate Allele Selectivity of SNP-Targeting Antisense Oligonucleotides
por: Østergaard, Michael E., et al.
Publicado: (2017)

Design and evaluation of locked nucleic acid-based splice-switching oligonucleotides in vitro
por: Shimo, Takenori, et al.
Publicado: (2014)

Nuclear and Cytoplasmatic Quantification of Unconjugated, Label-Free Locked Nucleic Acid Oligonucleotides
por: Pendergraff, Hannah, et al.
Publicado: (2020)

Drug discovery and development scheme for liver-targeting bridged nucleic acid antisense oligonucleotides
por: Wada, Fumito, et al.
Publicado: (2021)

Cell-permeable peptide nucleic acid antisense oligonucleotide platform targeting human betacoronaviruses
por: Park, Soree, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_l2c70inc61md1e214bvfgltkcg